Xcout Intel
ONCOPEPTIDES
Oncopeptides is a pharmaceutical company that develops targeted cancer therapies utilizing proprietary platforms like peptide drug conjugates. The company focuses on treating difficult-to-treat hematological diseases and rare cancers, such as multiple myeloma, aiming to provide new treatment options for patients with significant unmet medical needs.
Subscribe to see ONCOPEPTIDES’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ONCOPEPTIDES at a glance
ONCOPEPTIDES is a biotech company headquartered in United Kingdom. Xcout tracks 10 named people at ONCOPEPTIDES, including Sofia Heigis (Chief Executive Officer, CEO).
ONCOPEPTIDES leadership
- Sofia HeigisChief Executive Officer, CEO
- Eva NordströmChief Operating Officer (COO) and Deputy Managing Director
- Henrik BergentoftChief Financial Officer (CFO)
- Stefan NorinChief Medical Officer (CMO)
- Per Wold-OlsenChairman
- Lotta LarssonHead of Human Resources
4 more named people on record for ONCOPEPTIDES, with roles, board committees and tenure — see the full roster →
ONCOPEPTIDES competitors
A few of ONCOPEPTIDES's closest competitors — see the full list of competitors and alternatives →
Alpha-9 Oncology is a clinical-stage radiopharmaceutical company that develops targeted, bespoke molecules using peptide engineering and iterative design to treat cancer patients with precision. The company advances a portfolio of radiotherapeutics utilizing optimized binders, linkers, chelators, and radioisotopes for solid tumors.
NBE-Therapeutics is a biotechnology company founded in 2012 and headquartered in Basel, Switzerland, focused on developing antibody-drug conjugates for oncology treatments.
Adcytherix is a clinical-stage biopharmaceutical company that develops next-generation antibody-drug conjugates (ADCs) for oncology. The company combines clinically validated targets with innovative payloads derived from approved cancer drugs to treat resistant cancers and address unmet medical needs.
Cybrexa Therapeutics is a clinical-stage oncology biotechnology company that develops tumor-targeting peptide-drug conjugates (PDCs) for cancer patients. Its proprietary alphalex technology uses a pH-driven approach for antigen-independent, intracellular delivery of anti-cancer agents directly to tumors and metastases.
Active Biotech is a biotechnology company that develops pharmaceutical treatments for cancer and inflammatory eye diseases, focusing on specialist indications such as hematological cancers, solid tumors, and non-infectious uveitis. Its clinical pipeline includes immunomodulating molecules and antibody-based therapies like tasquinimod, laquinimod, and naptumomab.
Opna Bio is a clinical-stage biopharmaceutical company that discovers and develops novel oncology therapeutics targeting key regulators of cancer. Its pipeline includes epigenetic inhibitors such as OPN-6602 for multiple myeloma and zavabresib for myelofibrosis.
Get ONCOPEPTIDES's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on ONCOPEPTIDES in Xcout Intel
- 10 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access